



Recombinant Human Fluorescent Claudin18.2 VLP (DAG-WT1230)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Species	Human
Purity	> 95% as determined by HPLC
Conjugate	GFP
Applications	ELISA, SPR
Molecular Weight	29 kDa
Format	Liquid
Size	100 µg, 500 µg
Buffer	PBS, pH 7.4
Preservative	None
Storage	Stable at -80°C for 12 months

BACKGROUND

Introduction	Claudin-18.2 (CLDN18.2) has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer (GC), gastroesophageal junction (GEJ) cancer, esophageal cancer, and pancreatic cancer, because of its limited expression in healthy tissues and abnormal overexpression in a range of malignancies. Multiple clinical trials of CLDN18.2-targeted therapies, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies, are ongoing, with some showing promising early results.
--------------	--

KeywordsClaudin-18.2; CLDN18.2

GENE INFORMATION**UniProt ID**P56856-2
